Careers: Join Our Team


Translational Medicine, Chief Medical Officer

Position Summary:


The Translational Medicine, Chief Medical Officer (TM-CMO), is a physician scientist who will translate preclinical data into early clinical trial design and execution.  In this role, the TM-CMO will work with cross functional experts to interpret preclinical data packages of in-licensed therapies and create a roadmap for further nonclinical and clinical development that best translates a given mechanism into the clinic.   The TM-CMO will contribute creative problem-solving skills and strategies to enhance development timelines.

Position Responsibilities:

  • Understand, interpret, and translate preclinical data to clinical design:

    • Provide input to cross functional program teams on pre-clinical activities that will best support clinical development (e.g., pharmacology models, clinical pharmacology, biomarker development)

    • Lead development of the target product profile for a given therapy


  • Develop Clinical Strategy:

    • Maintain a high level of clinical and scientific expertise in a disease area(s) and relevant pathways by reviewing the literature, attending medical/scientific meetings, and through interchanges with consultants, thought leaders, investigators and internal stakeholders

    • Design fit for purpose Phase I and Phase II trials to enable rapid entry to clinic and proof of mechanism

    • Lead the design and implementation of a clinical development program in support of the overall product development plan, based on strong medical and scientific principles, knowledge of compliance and regulatory requirements, markets, business operations, and emerging issues

    • Lead publication strategy, including authoring manuscripts and collaborating with cross-functional colleagues and thought leaders to meet publication plan objectives


  • Operationalize and oversee early-stage clinical trials:

    • Design, initiate, conduct, oversee and analyze data from first-in-human and proof-of-concept studies

    • Serve as a key representative to health authorities in matters that focus on early clinical development

    • Lead all safety and medical interactions with relevant stakeholders

    • Contribute to a therapy’s planned regulatory filings including authoring clinical sections for INDs

    • Maintain ethical standards of the highest level and have the knowledge and ability to comply with all relevant ethical, regulatory, and legal standards


  • Input into due diligence efforts for in licensing of new compounds:

    • Serve as a scientific and clinical advisor to the Aditum Bio investing team on diligence of new therapies

Position Qualifications:

  • MD or MD/PhD with a minimum of 5-8 years of experience in clinical development in a pharmaceutical or biotech company setting

  • Deep experience working on early stage development programs and design (pre-IND, IND, and Phase 1)

  • Ability to run a clinical program with minimal direction

  • Extensive knowledge of clinical trial methodology, regulatory and compliance requirements governing clinical trials, and experience in development of clinical strategy and the design of study protocols

  • Proven leadership skills and ability to bring out the best in others on a cross-functional team; highly collaborative, team oriented and decisive

  • Experience leading within a matrix organization, with excellent communication skills, managing vendors and contract research associations

Company Overview:


Aditum Bio is a new model of biotech venture capital uniquely positioned to rapidly translate scientific discoveries into innovative new medicines. Aditum brings together unmatched scientific and domain expertise, combined with operational capabilities. Our agile operating model enables rapid company formation, planning, and execution for a new model of drug development. We target clinic-ready therapies to help underserved patient populations, rapidly forming companies and staffing them with medical and scientific experts. Launched in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, Aditum currently manages a broad portfolio of clinical stage companies with multiple drug candidates entering Phase 2 clinical trials in 2022.

Aditum Bio provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws.